Baseline susceptibility of primary human immunodeficiency virus type 1 to entry inhibitors

被引：90

作者：

Labrosse, B

Labernardière, JL

Dam, E

Trouplin, V

Skrabal, K

Clavel, F

Mammano, F

机构：

[1] Hop Bichat Claude Bernard, Unite Rech Antivirale, INSERM, U552, F-75018 Paris, France

[2] Viralliance SAS, Paris, France

来源：

JOURNAL OF VIROLOGY | 2003年 / 77卷 / 02期

关键词：

D O I：

10.1128/JVI.77.2.1610-1613.2003

中图分类号：

Q93 [微生物学];

学科分类号：

071005 ; 100705 ;

摘要：

Human immunodeficiency virus type 1 plasma viruses from 29 entry inhibitor-naive patients were characterized for their susceptibilities to T-20, AMD3100, and RANTES. A strikingly wide range of susceptibilities to T-20 was observed that was influenced by coreceptor usage but not by the susceptibilities of the viruses to inhibitors that target the chemokine receptors or by polymorphisms in the gp41 N helix.

引用

页码：1610 / 1613

页数：4

共 50 条

[41] Drug susceptibility of subtypes A, B, C, D, and E human immunodeficiency virus type 1 primary isolates
Palmer, S
Alaeus, A
Albert, J
Cox, S
AIDS RESEARCH AND HUMAN RETROVIRUSES, 1998, 14 (02) : 157 - 162
[42] In vitro phenotypic susceptibility of human immunodeficiency virus type 2 clinical isolates to protease inhibitors
Desbois, Delphine
Roquebert, Benedicte
Peytavin, Gilles
Damond, Florence
Collin, Gilles
Bernard, Antoine
Campa, Pauline
Matheron, Sophie
Chene, Genevieve
Brun-Vezinet, Francoise
Descamps, Diane
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2008, 52 (04) : 1545 - 1548
[43] Himalayan bioactive molecules as potential entry inhibitors for the human immunodeficiency virus
Bhardwaj, Vijay Kumar
Purohit, Rituraj
Kumar, Sanjay
FOOD CHEMISTRY, 2021, 347
[44] A novel phenotypic drug susceptibility assay for human immunodeficiency virus type 1
Petropoulos, CJ
Parkin, NT
Limoli, KL
Lie, YS
Wrin, T
Huang, W
Tian, H
Smith, D
Winslow, GA
Capon, DJ
Whitcomb, JM
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2000, 44 (04) : 920 - 928
[45] Primary infection by type 1 human immunodeficiency virus: Diagnosis and prognosis
Vanhems, P
Beaulieu, R
POSTGRADUATE MEDICAL JOURNAL, 1997, 73 (861) : 403 - 408
[46] Susceptibility of primary viruses to entry inhibitors
Labrosse, B
Labernardière, JL
Dam, E
Trouplin, V
Clavel, F
Mammano, F
ANTIVIRAL THERAPY, 2002, 7 : S110 - S110
[47] A recombinant retroviral system for rapid in vivo analysis of human immunodeficiency virus type 1 susceptibility to reverse transcriptase inhibitors
Shi, CF
Mellors, JW
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1997, 41 (12) : 2781 - 2785
[48] Human immunodeficiency virus type 1 entry and chemokine receptors: a new therapeutic target
Cammack, N
ANTIVIRAL CHEMISTRY & CHEMOTHERAPY, 1999, 10 (02): : 53 - 62
[49] Involvement of clathrin-mediated endocytosis in human immunodeficiency virus type 1 entry
Daecke, J
Fackler, OT
Dittmar, MT
Kräusslich, HG
JOURNAL OF VIROLOGY, 2005, 79 (03) : 1581 - 1594
[50] Inhibitors of human immunodeficiency virus type I integration
Hazuda, Daria J.
CURRENT OPINION IN HIV AND AIDS, 2006, 1 (03) : 212 - 217

← 1 2 3 4 5 →